Search

Your search keyword '"Garfinkle, Elizabeth A. R."' showing total 12 results
Start Over Author "Garfinkle, Elizabeth A. R." Search Limiters Peer Reviewed
12 results on '"Garfinkle, Elizabeth A. R."'

1. Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia

Author

Goda, Chinmayee, Kulkarni, Rohan, Bustos, Yaphet, Li, Wenjun, Rudich, Alexander, Balcioglu, Ozlen, Chidester, Sadie, Urs, Amog P., Karunasiri, Malith, Al-Marrawi, Yzen, Korn, Erin, Kanna, Sanjay, Garfinkle, Elizabeth A. R., Shah, Nisarg, Wooten, Ashley, Mundy-Bosse, Bethany, Sehgal, Lalit, Zhang, Bin, Marcucci, Guido, Mardis, Elaine R., Garzon, Ramiro, Bowman, Robert L., Viny, Aaron D., Miles, Linde A., Miller, Katherine E., and Dorrance, Adrienne M.

Published
2025
Full Text
View/download PDF

2. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia

Author

Stiff, Andrew, Fornerod, Maarten, Kain, Bailee N., Nicolet, Deedra, Kelly, Benjamin J., Miller, Katherine E., Mrózek, Krzysztof, Boateng, Isaiah, Bollas, Audrey, Garfinkle, Elizabeth A. R., Momoh, Omolegho, Fasola, Foluke A., Olawumi, Hannah O., Mencia-Trinchant, Nuria, Kloppers, Jean F., van Marle, Anne-Cecilia, Hu, Eileen, Wijeratne, Saranga, Wheeler, Gregory, Walker, Christopher J., Buss, Jill, Heyrosa, Adrienne, Desai, Helee, Laganson, Andrea, Hamp, Ethan, Abu-Shihab, Yazan, Abaza, Hasan, Kronen, Parker, Sen, Sidharth, Johnstone, Megan E., Quinn, Kate, Wronowski, Ben, Hertlein, Erin, Miles, Linde A., Mims, Alice S., Oakes, Christopher C., Blachly, James S., Larkin, Karilyn T., Mundy-Bosse, Bethany, Carroll, Andrew J., Powell, Bayard L., Kolitz, Jonathan E., Stone, Richard M., Duarte, Cassandra, Abbott, Diana, Amaya, Maria L., Jordan, Craig T., Uy, Geoffrey L., Stock, Wendy, Archer, Kellie J., Paskett, Electra D., Guzman, Monica L., Levine, Ross L., Menghrajani, Kamal, Chakravarty, Debyani, Berger, Michael F., Bottomly, Daniel, McWeeney, Shannon K., Tyner, Jeffrey W., Byrd, John C., Salomonis, Nathan, Grimes, H. Leighton, Mardis, Elaine R., and Eisfeld, Ann-Kathrin

Published
2024
Full Text
View/download PDF

5. Combinatorial macrophage induced innate immunotherapy against Ewing sarcoma: Turning “Two Keys” simultaneously

Author

Luo, Wen, Hoang, Hai, Miller, Katherine E., Zhu, Hongwen, Xu, Serena, Mo, Xiaokui, Garfinkle, Elizabeth A. R., Costello, Heather, Wijeratne, Saranga, Chemnitz, Wiebke, Gandhi, Ronan, Liao, Yanling, Ayello, Janet, Gardenswartz, Aliza, Rosenblum, Jeremy M., Cassady, Kevin A., Mardis, Elaine R., Lee, Dean A., Cripe, Timothy P., and Cairo, Mitchell S.

Published
2024
Full Text
View/download PDF

6. Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia

Author

Kamens, Jennifer L., Nance, Stephanie, Koss, Cary, Xu, Beisi, Cotton, Anitria, Lam, Jeannie W., Garfinkle, Elizabeth A. R., Nallagatla, Pratima, Smith, Amelia M. R., Mitchell, Sharnise, Ma, Jing, Currier, Duane, Wright, William C., Kavdia, Kanisha, Pagala, Vishwajeeth R., Kim, Wonil, Wallace, LaShanale M., Cho, Ji-Hoon, Fan, Yiping, Seth, Aman, Twarog, Nathaniel, Choi, John K., Obeng, Esther A., Hatley, Mark E., Metzger, Monika L., Inaba, Hiroto, Jeha, Sima, Rubnitz, Jeffrey E., Peng, Junmin, Chen, Taosheng, Shelat, Anang A., Guy, R. Kiplin, and Gruber, Tanja A.

Published
2023
Full Text
View/download PDF

7. Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center.

Author

Kebede, Ann M., Garfinkle, Elizabeth A. R., Mathew, Mariam T., Varga, Elizabeth, Colace, Susan I., Wheeler, Gregory, Kelly, Benjamin J., Schieffer, Kathleen M., Miller, Katherine E., Mardis, Elaine R., Cottrell, Catherine E., and Potter, Samara L.

Subjects
NUCLEOTIDE sequencing, SINGLE nucleotide polymorphisms, HEMATOLOGIC malignancies, PEDIATRIC oncology, PEDIATRIC therapy
Abstract

Despite the increasing availability of comprehensive next generation sequencing (NGS), its role in characterizing pediatric hematologic malignancies remains undefined. We describe findings from comprehensive genomic profiling of hematologic malignancies at a pediatric tertiary care center. Patients enrolled on a translational research protocol to aid in cancer diagnosis, prognostication, treatment, and detection of cancer predisposition. Disease-involved samples underwent exome and RNA sequencing and analysis for single nucleotide variation, insertion/deletions, copy number alteration, structural variation, fusions, and gene expression. Twenty-eight patients with hematologic malignancies were nominated between 2018-2021. Eighteen individuals received both germline and somatic sequencing; two received germline sequencing only. Germline testing identified patients with cancer predisposition syndromes and non-cancer carrier states. Fifteen patients (15/18, 83%) had cancer-relevant somatic findings. Potential therapeutic targets were identified in seven patients (7/18, 38.9%); three (3/7, 42.9%) received targeted therapies and remain in remission an average of 47 months later. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors.

Author

Paudel, Siddhi N., Hutzen, Brian J., Miller, Katherine E., Garfinkle, Elizabeth A. R., Chun-Yu Chen, Pin-Yi Wang, Glaspell, Andrea M., Currier, Mark A., Ringwalt, Emily M., Boon, Louis, Mardis, Elaine R., Cairo, Mitchell S., Ratner, Nancy, Dodd, Rebecca D., Cassady, Kevin A., and Cripe, Timothy P.

Subjects
SCHWANNOMAS, PERIPHERAL nerve tumors, MYELOID-derived suppressor cells, MYELOID cells, HERPES simplex virus, AZACITIDINE, SMALL molecules
Abstract

Introduction: Malignant peripheral nerve sheath tumors (MPNST) pose a significant therapeutic challenge due to high recurrence rates after surgical resection and a largely ineffective response to traditional chemotherapy. An alternative treatment strategy is oncolytic viroimmunotherapy, which can elicit a durable and systemic antitumor immune response and is Food and Drug Administration (FDA)-approved for the treatment of melanoma. Unfortunately, only a subset of patients responds completely, underscoring the need to address barriers hindering viroimmunotherapy effectiveness. Methods: Here we investigated the therapeutic utility of targeting key components of the MPNST immunosuppressive microenvironment to enhance viroimmunotherapy's antitumor efficacy in three murine models, one of which showed more immunogenic characteristics than the others. Results: Myelomodulatory therapy with pexidartinib, a small molecule inhibitor of CSF1R tyrosine kinase, and the oncolytic herpes simplex virus T-VEC exhibited the most significant increase in median survival time in the highly immunogenic model. Additionally, targeting myeloid cells with the myelomodulatory therapy trabectedin, a small molecule activator of caspase-8 dependent apoptosis, augmented the survival benefit of T-VEC in a less immunogenic MPNST model. However, tumor regressions or shrinkages were not observed. Depletion experiments confirmed that the enhanced survival benefit relied on a T cell response. Furthermore, flow cytometry analysis following combination viroimmunotherapy revealed decreased M2 macrophages and myeloid-derived suppressor cells and increased tumor-specific gp70+ CD8 T cells within the tumor microenvironment. Discussion: In summary, our findings provide compelling evidence for the potential to leverage viroimmunotherapy with myeloid cell targeting against MPNST and warrant further investigation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors.

Author

Paudel, Siddhi N., Hutzen, Brian J., Miller, Katherine E., Garfinkle, Elizabeth A. R., Chun-Yu Chen, Pin-Yi Wang, Glaspell, Andrea M., Currier, Mark A., Ringwalt, Emily M., Boon, Louis, Mardis, Elaine R., Cairo, Mitchell S., Ratner, Nancy, Dodd, Rebecca D., Cassady, Kevin A., and Cripe, Timothy P.

Subjects
SCHWANNOMAS, PERIPHERAL nerve tumors
Abstract

This document is a corrigendum for an article titled "Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors." The corrigendum addresses an error in the legend for Figure 1, where the tumor models were mistakenly referred to as xenografts instead of syngeneic models. The corrected legend clarifies that the study used syngeneic tumor models. The authors apologize for the error and state that it does not affect the scientific conclusions of the article. [Extracted from the article]

Published
2024
Full Text
View/download PDF

11. Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study.

Author

Pinto, Emilia Modolo, Rodriguez-Galindo, Carlos, Pounds, Stanley B., Wang, Lei, Clay, Michael R., Neale, Geoffrey, Garfinkle, Elizabeth A. R., Lam, Catherine G., Levy, Carolyn Fein, Pappo, Alberto S., Zambetti, Gerard P., and Ribeiro, Raul C.

Published
2017
Full Text
View/download PDF

12. A review of North American Recent Radiolucina (Bivalvia, Lucinidae) with the description of a new species.

Author

Garfinkle, Elizabeth A. R.

Subjects
*LUCINIDAE, *BIOLOGICAL specimens, *SPECIES diversity, *BIOLOGICAL classification
Abstract

North American members in the genus Radiolucina are reviewed. A lectotype for the type species, Radiolucina amianta, is designated and descriptions and illustrations are provided. A description of a new species, Radiolucina jessicae, from the west coast of Mexico is presented. Key diagnostic species characteristics are outlined and compared among members of the genus. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results